Sunshine Other Operating Expenses vs Net Interest Income Analysis

SBFMW Stock  USD 0.17  0.04  19.05%   
Sunshine Biopharma financial indicator trend analysis is much more than just breaking down Sunshine Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sunshine Biopharma is a good investment. Please check the relationship between Sunshine Biopharma Other Operating Expenses and its Net Interest Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Other Operating Expenses vs Net Interest Income

Other Operating Expenses vs Net Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sunshine Biopharma Other Operating Expenses account and Net Interest Income. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Sunshine Biopharma's Other Operating Expenses and Net Interest Income is 0.95. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Sunshine Biopharma Warrant, assuming nothing else is changed. The correlation between historical values of Sunshine Biopharma's Other Operating Expenses and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Sunshine Biopharma Warrant are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Other Operating Expenses i.e., Sunshine Biopharma's Other Operating Expenses and Net Interest Income go up and down completely randomly.

Correlation Coefficient

0.95
Relationship DirectionPositive 
Relationship StrengthVery Strong

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sunshine Biopharma. It is also known as Sunshine Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.
Most indicators from Sunshine Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to climb to about 428.6 K in 2024, despite the fact that Issuance Of Capital Stock is likely to grow to (8.6 M).
 2021 2022 2023 2024 (projected)
Other Operating Expenses2.7M13.0M28.9M30.3M
Interest Expense328.8K39.4K137.3K148.9K

Sunshine Biopharma fundamental ratios Correlations

0.981.0-0.99-0.941.00.990.99-0.160.10.970.971.0-0.280.530.260.320.990.350.990.920.980.960.730.76-1.0
0.980.97-0.97-0.930.980.980.98-0.090.120.950.980.98-0.230.610.170.340.960.440.980.880.950.910.680.69-0.99
1.00.97-1.0-0.921.00.990.99-0.160.050.960.961.0-0.290.480.290.30.990.310.990.930.990.960.730.75-0.99
-0.99-0.97-1.00.92-0.99-0.99-0.990.17-0.05-0.95-0.96-1.00.29-0.52-0.21-0.28-0.98-0.36-0.98-0.91-0.97-0.94-0.7-0.741.0
-0.94-0.93-0.920.92-0.93-0.93-0.930.05-0.35-0.99-0.97-0.940.21-0.6-0.29-0.43-0.93-0.43-0.93-0.78-0.92-0.91-0.81-0.790.94
1.00.981.0-0.99-0.930.990.99-0.130.070.970.971.0-0.280.520.260.320.990.340.990.920.980.960.720.74-1.0
0.990.980.99-0.99-0.930.991.0-0.160.120.960.980.99-0.280.610.140.290.970.450.980.880.950.910.660.75-0.99
0.990.980.99-0.99-0.930.991.0-0.160.120.960.980.99-0.280.610.140.290.970.450.980.880.950.910.660.75-0.99
-0.16-0.09-0.160.170.05-0.13-0.16-0.160.07-0.08-0.13-0.160.01-0.07-0.030.1-0.16-0.02-0.11-0.23-0.14-0.140.05-0.180.12
0.10.120.05-0.05-0.350.070.120.120.070.260.270.1-0.20.53-0.030.260.090.540.04-0.110.050.050.150.27-0.1
0.970.950.96-0.95-0.990.970.960.96-0.080.260.980.97-0.250.560.320.40.970.380.960.850.960.950.790.79-0.97
0.970.980.96-0.96-0.970.970.980.98-0.130.270.980.97-0.250.680.170.360.950.510.960.840.930.90.70.75-0.97
1.00.981.0-1.0-0.941.00.990.99-0.160.10.970.97-0.280.530.250.310.990.360.990.910.980.950.720.75-1.0
-0.28-0.23-0.290.290.21-0.28-0.28-0.280.01-0.2-0.25-0.25-0.28-0.1-0.080.11-0.29-0.08-0.27-0.42-0.27-0.27-0.04-0.360.29
0.530.610.48-0.52-0.60.520.610.61-0.070.530.560.680.53-0.1-0.50.220.460.950.530.260.380.30.140.43-0.55
0.260.170.29-0.21-0.290.260.140.14-0.03-0.030.320.170.25-0.08-0.50.230.34-0.670.230.410.430.530.650.22-0.22
0.320.340.3-0.28-0.430.320.290.290.10.260.40.360.310.110.220.230.340.130.320.240.330.340.380.27-0.31
0.990.960.99-0.98-0.930.990.970.97-0.160.090.970.950.99-0.290.460.340.340.280.970.920.990.970.760.75-0.98
0.350.440.31-0.36-0.430.340.450.45-0.020.540.380.510.36-0.080.95-0.670.130.280.360.090.190.1-0.050.37-0.38
0.990.980.99-0.98-0.930.990.980.98-0.110.040.960.960.99-0.270.530.230.320.970.360.930.970.940.720.77-0.99
0.920.880.93-0.91-0.780.920.880.88-0.23-0.110.850.840.91-0.420.260.410.240.920.090.930.940.930.670.73-0.91
0.980.950.99-0.97-0.920.980.950.95-0.140.050.960.930.98-0.270.380.430.330.990.190.970.940.990.80.74-0.97
0.960.910.96-0.94-0.910.960.910.91-0.140.050.950.90.95-0.270.30.530.340.970.10.940.930.990.830.72-0.94
0.730.680.73-0.7-0.810.720.660.660.050.150.790.70.72-0.040.140.650.380.76-0.050.720.670.80.830.59-0.73
0.760.690.75-0.74-0.790.740.750.75-0.180.270.790.750.75-0.360.430.220.270.750.370.770.730.740.720.59-0.74
-1.0-0.99-0.991.00.94-1.0-0.99-0.990.12-0.1-0.97-0.97-1.00.29-0.55-0.22-0.31-0.98-0.38-0.99-0.91-0.97-0.94-0.73-0.74
Click cells to compare fundamentals

Sunshine Biopharma Account Relationship Matchups

Sunshine Biopharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets98.1K1.0M2.2M29.2M27.3M28.7M
Total Current Liabilities833.5K1.1M91.2K6.9M5.6M5.8M
Total Stockholder Equity(735.4K)(954.8K)211.7K21.6M21.2M22.3M
Net Debt675.1K923.2K(145.2K)(17.6M)(15.6M)(14.9M)
Retained Earnings(17.4M)(20.2M)(32.7M)(59.4M)(63.9M)(60.7M)
Accounts Payable96.9K62.9K42.9K2.8M2.6M2.7M
Cash40.5K989.9K2.0M21.8M16.3M17.1M
Cash And Short Term Investments40.5K989.9K2.0M21.8M16.3M17.1M
Common Stock Shares Outstanding218.7K866.01.3K7.6K12.2K11.6K
Liabilities And Stockholders Equity98.1K1.0M2.2M29.2M27.3M28.7M
Non Current Liabilities Total812.5K949.0K1.9M685.3K587.8K480.3K
Other Stockholder Equity16.6M19.2M32.8M80.8M84.4M88.6M
Total Liab833.5K2.0M2.0M7.6M6.1M6.4M
Total Current Assets65.7K1.0M2.2M27.3M24.9M26.1M
Common Stock35.3K346.4K2.6K22.6K28.0K26.6K
Short Long Term Debt Total715.6K1.9M1.9M4.3M657.7K1.0M
Other Current Liab21.1K24.3K48.3K(2.7M)2.5M2.7M
Other Current Assets8.8K10.4K37.2K283.8K310.6K326.1K
Short Term Debt715.6K964.1K1.9M3.8M118.7K112.7K
Property Plant And Equipment Net32.5K19.5K7.1K1.2M1.0M1.1M
Non Current Assets Total32.5K19.5K7.1K1.9M2.5M2.6M
Net Receivables430.01.9K7.8K1.9M2.6M2.7M
Accumulated Other Comprehensive Income(2.5K)(2.9K)(23.1K)161.8K696.1K730.9K
Net Tangible Assets(105.8K)(785.4K)(1.1M)111.7K128.4K134.8K
Property Plant Equipment45.1K32.5K19.5K7.1K6.4K6.0K
Net Invested Capital(69.8K)858.3K2.0M25.3M21.2M22.3M
Capital Stock85.3K446.4K102.6K23.6K29.0K27.6K
Net Working Capital(767.8K)(25.4K)2.1M20.4M19.3M20.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.